Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Talo-patello-scaphoid osteolysis is an extremely rare form of primary osteolysis, described in two sisters to date, characterized by bilateral osteolysis of the tali, scaphoids, and patellae (accompanied by periarticular swelling and pain) and short fourth metacarpals (brachydactyly type E), in the absence of renal disease. Autosomal recessive inheritance has been suggested.
Features include very common findings: Enlarged joints, Osteolysis of scaphoids, Osteolysis of patellae, and Osteolysis of talus and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 4 | Enlarged joints, Osteolysis of scaphoids, Osteolysis of patellae |
Phenotype severity distribution: 6 very common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for talo-patello-scaphoid osteolysis.
100 publications have been identified in PubMed for talo-patello-scaphoid osteolysis. Kisho has analyzed 54 by research type. Research spans Review / Meta-Analysis (69%), Gene Therapy / Novel Therapeutics (15%), and Basic Science / Preclinical (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 37 | 69% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 6:51 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
New treatment approaches |
8 |
15% |
Laboratory research | 4 | 7% |
Disease patterns and progression | 3 | 6% |
Patient case studies | 1 | 2% |
Clinical study results | 1 | 2% |
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Gene Therapy / Novel Therapeutics]
Walther LE (2025). [PMID: 40192781](https://pubmed.ncbi.nlm.nih.gov/40192781/). *HNO*. [Review / Meta-Analysis]
Brokke KE (2025). [PMID: 40634186](https://pubmed.ncbi.nlm.nih.gov/40634186/). *Br J Anaesth*. [Review / Meta-Analysis]
Kaul A (2025). [PMID: 40915300](https://pubmed.ncbi.nlm.nih.gov/40915300/). *Lancet Rheumatol*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Gencer NS (2025). [PMID: 41291504](https://pubmed.ncbi.nlm.nih.gov/41291504/). *BMC Geriatr*. [Epidemiology / Natural History]
Jachiet V (2025). [PMID: 40476413](https://pubmed.ncbi.nlm.nih.gov/40476413/). *Rev Prat*. [Review / Meta-Analysis]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Dev Med Child Neurol*. [Review / Meta-Analysis]
Yacoub MR (2025). [PMID: 40747632](https://pubmed.ncbi.nlm.nih.gov/40747632/). *Curr Opin Allergy Clin Immunol*. [Review / Meta-Analysis]